Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Consolidated Net Income (2021 - 2025)

Historic Consolidated Net Income for Kezar Life Sciences (KZR) over the last 5 years, with Q2 2025 value amounting to -$13.7 million.

  • Kezar Life Sciences' Consolidated Net Income rose 3639.95% to -$13.7 million in Q2 2025 from the same period last year, while for Sep 2025 it was -$50.5 million, marking a year-over-year increase of 4729.69%. This contributed to the annual value of -$83.7 million for FY2024, which is 1780.11% up from last year.
  • According to the latest figures from Q2 2025, Kezar Life Sciences' Consolidated Net Income is -$13.7 million, which was up 3639.95% from -$16.6 million recorded in Q1 2025.
  • Kezar Life Sciences' 5-year Consolidated Net Income high stood at -$13.0 million for Q2 2021, and its period low was -$32.3 million during Q4 2023.
  • For the 5-year period, Kezar Life Sciences' Consolidated Net Income averaged around -$19.2 million, with its median value being -$18.2 million (2022).
  • As far as peak fluctuations go, Kezar Life Sciences' Consolidated Net Income crashed by 7743.8% in 2023, and later surged by 3732.8% in 2024.
  • Over the past 5 years, Kezar Life Sciences' Consolidated Net Income (Quarter) stood at -$14.2 million in 2021, then fell by 27.93% to -$18.2 million in 2022, then plummeted by 77.44% to -$32.3 million in 2023, then soared by 37.33% to -$20.2 million in 2024, then skyrocketed by 32.22% to -$13.7 million in 2025.
  • Its Consolidated Net Income was -$13.7 million in Q2 2025, compared to -$16.6 million in Q1 2025 and -$20.2 million in Q4 2024.